Cost-effectiveness of direct-acting antivirals for chronic hepatitis C virus in the United States from a payer perspective

BACKGROUND: Direct-acting antivirals (DAAs) have been a breakthrough therapeutic innovation in the treatment of chronic hepatitis C virus (HCV) with significantly improved efficacy, safety, and tolerability. OBJECTIVE: To evaluate the cost-effectiveness of treating patients with HCV with DAAs compar...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaplan, David E, Serper, Marina, Kaushik, Ankita, Durkin, Claire, Raad, Angie, El-Moustaid, Fadoua, Smith, Nathaniel, Yehoshua, Alon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373042/
https://www.ncbi.nlm.nih.gov/pubmed/36125059
http://dx.doi.org/10.18553/jmcp.2022.28.10.1138

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373042/
https://www.ncbi.nlm.nih.gov/pubmed/36125059
http://dx.doi.org/10.18553/jmcp.2022.28.10.1138

Ejemplares similares